Viveka Roychowdhury

Mumbai

Editor, Express Pharma and Express Healthcare at The Indian Express

Ex microbiologist, now pharma & healthcare journalist. Views own, re tweets not endorsements. Editor, Express Pharma & Express Healthcare, Indian Express

Featured in: Favicon

indianexpress.com Favicon

expresspharma.in Favicon

financialexpress.com Favicon

expressbpd.com Favicon

expresshealthcare.in Favicon

businessfortnight.com

Articles

We are well-aligned to capitalise on the CDMO opportunity

6 days ago | expresspharma.in | Viveka Roychowdhury

Share India may today account for less than 2–3 per cent of the pharma CDMO market today but has the potential to grow from $3.5 billion to $25 billion.
The case for taller hospitals

1 week ago | expresshealthcare.in | Viveka Roychowdhury

Share Speaking at FICCI’s recently held Medical Value Travel Conference, NITI Aayog member Prof Vinod K Paul called for industry suggestions on reducing compliance burdens for healthcare facilities.
How counterfeiters are breaching India’s QR code system

1 week ago | expresspharma.in | Viveka Roychowdhury

Share There is growing concern that a sizable proportion of medicines in India could be unsafe for patients. For example, on April 19, 2025, CDSCO published three lists of Not of Standard Quality (NSQ) drug alerts for March 2025, spanning 131 product batches. The most common reason cited is failing the dissolution test as per IP 2022.
The use of FTWZs has risen by 20 to 25% every quarter after the pandemic

1 month ago | expresspharma.in | Viveka Roychowdhury

Share With close to three decades of experience in setting up logistics parks at ports, across MENA and India, you have seen the evolution of pharma logistics. What are the key drivers for the current transformation of the pharma and medical device logistics sector in India? And where do free trade warehousing zones (FTWZs) fit into these business imperatives?
N-FIS was developed to address a critical challenge in healthcare—needle phobia - Express Pharma

1 month ago | expresspharma.in | Viveka Roychowdhury

Share Give a short background of the founders IntegriMedical is led by a team of experienced professionals with a strong background in medical technology, business development and healthcare innovation. The key leadership team includes myself, Ankur Naik, MD, Scott McFarland, CEO and Mark Timm, COO.
Tit for tat tariffs highlight need to up our game

1 month ago | expresshealthcare.in | Viveka Roychowdhury

In fact, tariffs on medical device imports could achieve exactly the opposite effect of their initial intent. As Choudary points out, “Economies prosper when they focus on their strengths, leveraging comparative advantages to enhance global trade. However, by disrupting supply chains through excessive tariffs, the US risks not only reducing efficiency but also increasing healthcare costs for its own citizens.
US tariffs, IP issues threaten patient access

1 month ago | expresspharma.in | Viveka Roychowdhury

Share On April 2, US President Trump is expected to follow through on his threats to impose 25 per cent tariffs on drug imports from India. And even if the tariff announcements are deferred or lower than expected, the US Trade Representative (US TR)’s latest report gives some clues that the re-calibration indicated by President Trump will continue.
AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

1 month ago | expresspharma.in | Viveka Roychowdhury

Share What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.
Will private hospitals’ capex spur medical inflation?

2 months ago | expresshealthcare.in | Viveka Roychowdhury

160 Share A Right To Information (RTI) query to the Ministry of Health & Family Welfare on the dues payable to empaneled hospitals who have given free treatment to patients under Ayushman Bharat Yojana received a reply dated February 28, that dues of Rs 1,21,61,45,63,617 (approximately Rs 12,161.45 crores) are pending.
Balancing MAGA and MIGA

2 months ago | expresspharma.in | Viveka Roychowdhury

Share Pharma experts scouring the joint statement issued at the end of the talks between Prime Minister Modi and President Trump seized on para 18 of the 33-point statement which expands on the US-India TRUST (Transforming the Relationship Utilising Strategic Technology) initiative.